|
Dr. Cunningham is the Chief Executive Officer of RLIP Pharmaceuticals, an early-stage biotechnology company that is developing therapies for radiation toxicity. Prior to this position, Dr. Cunningham was the Associate Director of the Mary Crowley Medical Research Center, an early phase drug development institute in Dallas, Texas. His background includes academic positions at the Medical College of Wisconsin and Harvard Medical School where he conducted basic cell biology research for a number of years. He has published numerous papers in the areas of both basic and clinical research. Dr. Cunningham acts as a consultant to many pharmaceutical development companies and serves on several scientific advisory boards. | 